Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul;9(7):e61.
doi: 10.1016/S2213-2600(21)00212-5. Epub 2021 May 12.

Inhaled budesonide for early treatment of COVID-19 - Authors' reply

Sanjay Ramakrishnan  1 , Mona Bafadhel  2
Affiliations
Comment

Inhaled budesonide for early treatment of COVID-19 - Authors' reply

Sanjay Ramakrishnan et al. Lancet Respir Med. 2021 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

SR reports grants and non-financial support from the National Institute for Health Research Biomedical Research Centre, during the conduct of the study; and non-financial support from AstraZeneca, personal fees from Australian Government Research Training Program, outside of the submitted work. MB reports grants from AstraZeneca, personal fees from AstraZeneca, Chiesi, GlaxoSmithKline, and scientific adviser to Albus Health and ProAxsis outside of the submitted work.

Comment on

  • Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.
    Ramakrishnan S, Nicolau DV Jr, Langford B, Mahdi M, Jeffers H, Mwasuku C, Krassowska K, Fox R, Binnian I, Glover V, Bright S, Butler C, Cane JL, Halner A, Matthews PC, Donnelly LE, Simpson JL, Baker JR, Fadai NT, Peterson S, Bengtsson T, Barnes PJ, Russell REK, Bafadhel M. Ramakrishnan S, et al. Lancet Respir Med. 2021 Jul;9(7):763-772. doi: 10.1016/S2213-2600(21)00160-0. Epub 2021 Apr 9. Lancet Respir Med. 2021. PMID: 33844996 Free PMC article. Clinical Trial.
  • Inhaled budesonide for early treatment of COVID-19.
    Zeitlinger M, Idzko M. Zeitlinger M, et al. Lancet Respir Med. 2021 Jul;9(7):e59. doi: 10.1016/S2213-2600(21)00215-0. Epub 2021 May 12. Lancet Respir Med. 2021. PMID: 33991506 Free PMC article. No abstract available.
  • Inhaled budesonide for early treatment of COVID-19.
    Choi JC, Kim WY. Choi JC, et al. Lancet Respir Med. 2021 Jul;9(7):e60. doi: 10.1016/S2213-2600(21)00217-4. Epub 2021 May 12. Lancet Respir Med. 2021. PMID: 33991507 Free PMC article. No abstract available.
  • Inhaled budesonide for early treatment of COVID-19.
    San-Juan R, Fernández-Ruiz M, López-Medrano F, Aguado JM. San-Juan R, et al. Lancet Respir Med. 2021 Jul;9(7):e58. doi: 10.1016/S2213-2600(21)00211-3. Epub 2021 May 12. Lancet Respir Med. 2021. PMID: 33991508 Free PMC article. No abstract available.

References

    1. Ramakrishnan S, Nicolau DV, Jr, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021 doi: 10.1016/S2213-2600(21)00160-0. published online April 9. - DOI - PMC - PubMed
    1. Butler CC, Dorward J, Yu L-M, et al. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;397:1063–1074. - PMC - PubMed
    1. Yu L-M, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv. 2021 doi: 10.1101/2021.04.10.21254672. published online April 12. (preprint). - DOI
    1. Jin H, Wang H, Li X, et al. Economic burden of COVID-19, China, January-March, 2020: a cost-of-illness study. Bull World Health Organ. 2021;99:112–124. - PMC - PubMed
    1. Ronco C, Reis T, Husain-Syed F. Management of acute kidney injury in patients with COVID-19. Lancet Respir Med. 2020;8:738–742. - PMC - PubMed